Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report
Frontiers in Pharmacology · 02.11.2026 · 17
DOI: 10.3389/fphar.2026.1969621 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.11.2026. Verfasst von Lijuan Cai und 5 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kunming Medical University.
Abstract (Originalsprache)
In the era of precision targeted therapy, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes for patients with ALK -positive non-small cell lung cancer (NSCLC). The third-generation ALK inhibitor lorlatinib, characterized by superior antitumor activity, a broader spectrum of ALK mutation sites and enhanced central nervous system (CNS) penetrability, has yielded breakthrough clinical benefits. However, lorlatinib has a distinct adverse event profile, with edema, dyslipidemia, central and peripheral nervous system toxicities, posing key clinical management challenges. Herein, we report the first case of an ALK -fusion NSCLC patient who developed peripheral neuropathy, dysarthria, and sensorineural deafness following lorlatinib treatment. While dysarthria and peripheral neuropathy have been previously documented, sensorineural deafness is extremely rare, and no prior reports describe the concurrent and persistent onset of all three symptoms, underscoring the need for enhanced toxicity monitoring and patient education.
Förderung
- Kunming Medical University
Zitieren
APA
Cai, L., Peng, W., Yang, R., Wu, J., Luo, C., & Yang, F. (2026). Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1969621
Vancouver
Cai L, Peng W, Yang R, Wu J, Luo C, Yang F. Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1969621
BibTeX
@article{Cai2026,
author = {Cai, Lijuan and Peng, Wenying and Yang, Runxiang and Wu, Jiao and Luo, Chunxiang and Yang, Fang},
title = {Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1969621}
}
EUVIMED